Literature DB >> 7540887

Purified CD34+ Lin- Thy+ stem cells do not contain clonal myeloma cells.

Y Gazitt1, C C Reading, R Hoffman, A Wickrema, D H Vesole, S Jagannath, J Condino, B Lee, B Barlogie, G Tricot.   

Abstract

High-dose therapy with autologous marrow or peripheral blood stem cell (PBSC) rescue has been extensively applied in the treatment of multiple myeloma (MM) patients during the past 10 years resulting in improved event-free and overall survival when compared with standard chemotherapy. However, relapses are common and cure is unlikely in the majority of patients. Because both bone marrow and PBSCs are contaminated with myeloma cells it is conceivable that relapse after autotransplantation originates at least in part from autografted tumor cells. In this study, mobilized PBSCs were examined for the presence of myeloma cells based on immunophenotyping and sensitive polymerase chain reaction (PCR)-based techniques. In addition, CD34+ Lin- Thy+ stem cells were purified from mobilized PBSC harvests of 10 MM patients by sequentially using counterflow elutriation centrifugation, treatment with phenylalanine methylester, and flow sorting, using 5-parameter gating (propidium iodide, forward scatter, side scatter, CD34+ v Lin- and CD34+ v Thy+). Virtually all mobilized unsorted PBSC preparations contained myeloma cells in sufficient quantities (range, < 0.01 to > 10%) potentially causing a disease relapse. Stem cell purification led to an overall enrichment by about 50-fold in all 10 patients; approximately 90% of the final cell population expressed CD34+ Lin- Thy+ with no evidence of myeloma cell contamination based on flow cytometric analysis of CD38bright cells (< 0.1%). Quantitative PCR amplification of patient-specific complementarity determining region III (CDRIII) DNA sequences showed depletion of clonal B cells by 2.7 to 7.3 logs, with the highest log reduction noted in the samples initially containing the most tumor cells. Our results show that purification of CD34+ Lin- Thy+ cells depletes myeloma cells to undetectable levels from up to 10% present in unsorted PBSCs, thus offering a tool to investigate whether MM relapse after autotransplantation can be reduced markedly.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7540887

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  15 in total

Review 1.  The hematopoietic system in the context of regenerative medicine.

Authors:  Christopher D Porada; Anthony J Atala; Graça Almeida-Porada
Journal:  Methods       Date:  2015-08-28       Impact factor: 3.608

Review 2.  Multiple myeloma: increasing evidence for a multistep transformation process.

Authors:  M Hallek; P L Bergsagel; K C Anderson
Journal:  Blood       Date:  1998-01-01       Impact factor: 22.113

3.  Assessment of IgH PCR strategies in multiple myeloma.

Authors:  R G Owen; R J Johnson; A C Rawstron; P A Evans; A Jack; G M Smith; J A Child; G J Morgan
Journal:  J Clin Pathol       Date:  1996-08       Impact factor: 3.411

Review 4.  Detection of minimal residual disease in multiple myeloma and acute leukaemia.

Authors:  M H Bakkus; N Juge-Morineau; J E van der Werff ten Bosch
Journal:  Med Oncol       Date:  1996-06       Impact factor: 3.064

Review 5.  Autologous peripheral blood stem cells: collection and processing.

Authors:  M Hansson; A Svensson; P Engervall
Journal:  Med Oncol       Date:  1996-06       Impact factor: 3.064

Review 6.  The road to purified hematopoietic stem cell transplants is paved with antibodies.

Authors:  Aaron C Logan; Irving L Weissman; Judith A Shizuru
Journal:  Curr Opin Immunol       Date:  2012-08-29       Impact factor: 7.486

Review 7.  [Transplantation of hematopoietic stem cells. II: Indications for transplantation of hematopoietic stem cells after myeloablative therapy].

Authors:  H Link; H J Kolb; W Ebell; D K Hossfeld; A Zander; D Niethammer; H Wandt; H Grosse-Wilde; U W Schaefer
Journal:  Med Klin (Munich)       Date:  1997-09-15

Review 8.  Multiple myeloma, high-dose treatment and autologous stem cell transplantation--current status.

Authors:  B Björkstrand
Journal:  Med Oncol       Date:  1996-03       Impact factor: 3.064

9.  Detection of clonal immunoglobulin gene rearrangements in the peripheral blood progenitor cells of patients with multiple myeloma: the potential role of purging with CD34 positive selection.

Authors:  R G Owen; A P Haynes; P A Evans; R J Johnson; A C Rawstron; G McQuaker; G M Smith; M C Galvin; D L Barnard; N H Russell; J A Child; G J Morgan
Journal:  Clin Mol Pathol       Date:  1996-04

10.  Immune reconstitution after autologous hematopoietic transplantation with Lin-, CD34+, Thy-1lo selected or intact stem cell products.

Authors:  Rakesh K Singh; Michelle L Varney; Cheryl Leutzinger; Julie M Vose; Philip J Bierman; Suleyman Buyukberber; Kazuhiko Ino; Kevin Loh; Craig Nichols; David Inwards; Robert Rifkin; James E Talmadge
Journal:  Int Immunopharmacol       Date:  2007-04-20       Impact factor: 4.932

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.